IRIS
ESPOSITO, MARIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.268
EU - Europa 1.159
AS - Asia 436
OC - Oceania 2
Totale 3.865
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.261
IE - Irlanda 698
CN - Cina 291
UA - Ucraina 150
SG - Singapore 110
DE - Germania 100
FR - Francia 56
SE - Svezia 48
IT - Italia 35
FI - Finlandia 18
GB - Regno Unito 18
TR - Turchia 16
BE - Belgio 13
CZ - Repubblica Ceca 8
IN - India 8
VN - Vietnam 6
CA - Canada 5
HU - Ungheria 3
TW - Taiwan 3
CR - Costa Rica 2
ES - Italia 2
NL - Olanda 2
PT - Portogallo 2
RS - Serbia 2
AT - Austria 1
AU - Australia 1
BN - Brunei Darussalam 1
EE - Estonia 1
JP - Giappone 1
LT - Lituania 1
LU - Lussemburgo 1
NZ - Nuova Zelanda 1
Totale 3.865
Salva come PNG Salva come JPEG
Città #
Dublin 696
Jacksonville 613
Chandler 469
Boardman 156
Lawrence 102
Princeton 102
Nanjing 75
Singapore 75
New York 72
Ann Arbor 71
Wilmington 66
Beijing 57
Dearborn 55
Shenyang 24
Los Angeles 22
Nanchang 22
Jinan 18
Hebei 17
Jiaxing 16
Ashburn 15
Dallas 14
Brussels 13
San Mateo 12
Izmir 11
Des Moines 10
Munich 10
Changsha 9
Brno 8
Lappeenranta 8
Norwalk 8
Houston 7
Kunming 7
Ningbo 7
Seattle 7
Woodbridge 7
Mountain View 6
Rome 6
Tianjin 6
Dong Ket 5
Helsinki 5
Milan 5
Zhengzhou 5
Fremont 4
Pune 4
Budapest 3
Fairfield 3
Hefei 3
Menlo Park 3
Redwood City 3
Taizhou 3
Aci Catena 2
Bremen 2
Chicago 2
Falls Church 2
Guangzhou 2
Haikou 2
Hangzhou 2
Hyderabad 2
L'aquila 2
Lanzhou 2
London 2
Lorraine 2
Madrid 2
Mumbai 2
Niš 2
Olbia 2
Paris 2
San José 2
Taipei 2
Tappahannock 2
Amsterdam 1
Ashington 1
Auburn Hills 1
Auckland 1
Bandar Seri Begawan 1
Baotou 1
Bologna 1
Bridge 1
Chengdu 1
Dornelas 1
Frankfurt am Main 1
Hanoi 1
Istanbul 1
Lanciano 1
Las Vegas 1
Lisbon 1
Luxembourg 1
L’Aquila 1
Melbourne 1
Monmouth Junction 1
Mont-Saint-Hilaire 1
New Orleans 1
Pescara 1
Phoenix 1
Prineville 1
Redmond 1
Richmond 1
Saint Louis 1
Santa Clara 1
Shanghai 1
Totale 3.015
Salva come PNG Salva come JPEG
Nome #
Frequency of melanocytic nevi in psoriatic patients is related to treatment and not to disease severity 73
A cost-utility analysis of etanercept for the treatment of moderate-to-severe psoriasis in Italy 69
Muir-Torre syndrome with fatal outcome 68
Prospective assessment of body weight and body composition changes in patients with psoriasis receiving anti-TNF-α treatment. 66
Interobserver agreement on dermoscopic features of pigmented basal cell carcinoma 57
Dermatiti da Piogeni o Piodermiti 56
Treatment of erytrodermic psoriasis with etanercept 56
A multicenter study on effectiveness and safety of risankizumab in psoriasis: an Italian 16-week real-life experience during the COVID-19 pandemic 56
Interobserver agreement on dermoscopic features of pigmented basal cell carcinoma 55
Systemic treatment: Ciclosporin 54
Influence and variation of the body mass index (BMI) in patients treated with etanercept for plaque-type psoriasis 49
Efficacy and Safety of Subcutaneous Anti-Tumor Necrosis Factor-Alpha Agents, Etanercept and Adalimumab, in Elderly Patients Affected by Psoriasis and Psoriatic Arthritis: An Observational Long-Term Study 48
Efficacy and safety of infliximab in teh treatment of severe or arthropathic psoriasis: preliminary results 47
Involvement of Ig heavy chain HS1,2-A enhancer*2 allele in dermatitis herpetiformis, plaque psoriasis and psoriatic arthritis 47
Quality of life 45
CONTINUOUS TREATMENT OF PLAQUE-TYPE PSORIASIS WITH ETANERCEPT: AN OBSERVATIONAL LONG-TERM EXPERIENCE 45
Association between psoriasis and periodontitis, and efficacy of anti-TNF-α therapy: a case series 45
Treatment of early stage mycosis fungoides with topical bexarotene 44
Treatment of erythrodermic psoriasis with etanercept 44
Disease Severity Is Associated with Alexithymia in Patients with Atopic Dermatitis 44
Clinical Variants 43
Clinical applications of PPI-TT guidelines on transitioning therapies in the treatment of moderate to severe psoriasis: an expert opinion of central Italy dermatologists 43
Clinical markers predictive of primary inefficacy: a "real life" retrospective study in psoriatic patients treated with etanercept. 43
Combination therapy with etanercept in psoriasis: Retrospective analysis of efficacy and safety outcomes from real-life practice 42
An Italian study on psoriasis and depression 41
Cutaneous body image in psoriasis: The role of attachment style and alexithymia 41
Differences in percutaneous absorption in normal and atopic dermatitis skin in relation to molecular weigh. 40
Use of etanercept in patients with psoriasis and concomitant hepatitis C infection 40
UVA1 Laser in the Treatment of Vitiligo 40
Brodalumab for the treatment of moderate-to-severe plaque-type psoriasis: a real-life, retrospective 24-week experience 40
High-dose initiation of etanercept in plaque psoriasis and psoriatic arthritis: an italian experience 39
Topical corticotherapy: the expert's opinion 39
Long-lasting remission of pemphigus vulgaris treated with rituximab 39
Certolizumab pegol for the treatment of psoriatic arthritis and plaque psoriasis 39
Betamethasone valerate dressing is non-inferior to calcipotriol-betamethasone dipropionate ointment in the treatment of patients with mild-to-moderate chronic plaque psoriasis: results of a randomized assessor-blinded multicentre trial 39
A 48-week update of a multicentre real-life experience of dupilumab in adult patients with moderate-to-severe atopic dermatitis 39
Dermatiti da piogeni o piodermiti 38
Association between Psoriasis and haplotypes of the IgH 3' Regulatory Region 1 38
Dose adjustment of biologic therapies for psoriasis in dermatological practice: a retrospective study. 38
UVB 308 nm XeCl excimer laser for mycosis fungoides 38
Unresponsiveness to etanercept: is there a common phenotipical profile of patients? 38
Haplotypes associated with alleles of the immunoglobulin heavy chain enhancer HS1,2 of the 3¢ regulatory region in patients with psor- iatic arthritis 38
A case of generalized pustular psoriasis and arthritis treated with ixekizumab 38
Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real-life study 38
Resolution of idiopathic recurrent pericarditis in a psoriatic arthritis patient treated with etanercept 37
Altered penetration of polyethylene glycols into uninvolved skin of atopic dermatitis patients. 37
Treatment adherence to different etanercept regimens, continuous vs. intermittent, in patients affected by plaque-type psoriasis 37
Consensus on the place in therapy of TNF-α inhibitors in the treatment of patients with chronic plaque psoriasis 37
Resolution with rituximab of localized scleroderma occurring during etanercept treatment in a patient with rheumatoid arthritis. 36
Some considerations about the importance of alliance between patients and dermatologists in psoriasis 36
PsA-Disk, a novel visual instrument to evaluate psoriatic arthritis in psoriatic patients: an Italian derma-rheuma multicentre study 36
Histopathology of the skin in rheumatic diseases 36
Clobetasol propionate foam 0.05% as a novel topical formulation for plaque-type and scalp psoriasis 35
Etanercept, childhood and long-term safety: a case of five years treatment. 35
Long-term efficacy of etanercept in hidradenitis suppurativa. 35
Psoriasis target therapy: ustekinumab 35
Long-term safety and efficacy of secukinumab in patients with psoriasis and major psychiatric disorders: a case series 35
Morbid obesity and psoriasis: Disease remission after laparoscopic sleeve gastrectomy 35
Comorbidities and treatment patterns in adult patients with atopic dermatitis: results from a nationwide multicenter study 35
Survival rate of antitumour necrosis factor- treatments for psoriasis in routine dermatological practice: a multicentre observational study 34
Long-term efficacy of infliximab therapy in plaque psoriasis and arthropathic psoriasis 34
INFLUENCE AND VARIATION OF THE BODY MASS INDEX IN PATIENTS TREATED WITH ETANERCEPT FOR PLAQUE-TYPE PSORIASIS 34
Efficacy and safety of adalimumab after failure of other anti-TNFα agents for plaque-type psoriasis: clinician behavior in real life clinical practice 34
Trimethoprim-sulfamethoxazole induced erythrodermic psoriasis 33
Potential Role of Cytochrome c and Tryptase in Psoriasis and Psoriatic Arthritis Pathogenesis: Focus on Resistance to Apoptosis and Oxidative Stress 33
Ixekizumab improves disease severity, clinical symptoms and quality of life in patients with genital psoriasis: A 24-week real-life experience 33
Treatment of vitiligo with the 308 nm excimer laser 32
High-dose initiation of etanercept in psoriatic arthritis and plaque psoriasis: Efficacy, safety and impact on patients' quality of life 32
Remission of psoriatic arthritis after etanercept discontinuation: analysis of patients' clinical characteristics leading to disease relapse 32
Involvement of interleukin-21 in the epidermal hyperplasia of psoriasis 32
Etanercept biosimilar SB4 in the treatment of plaque-type psoriasis and psoriatic arthritis: a single-centre, observational, retrospective, real-life study 32
Patients' demographic and socioeconomic characteristics influence the therapeutic decision-making process in psoriasis 32
A 52-week update of a multicentre real-life experience on effectiveness and safety of risankizumab in psoriasis 32
Hepatitis B reactivation in psoriasis patients treated with anti-TNF agents: prevention and management 31
Psoriasis and its management in women of childbearing age: Tools to increase awareness in dermatologists and patients 31
Effect of anti tumor necrosis factor-alpha therapies on body composition in patients with psoriasis 30
Efficacy and Safety of Etanercept in Psoriasis after Switching from Other Treatments An Observational Study 30
Entecavir and intermittent etanercept therapy in a patient with concurrent hepatitis B virus infection and psoriasis 30
Depressive symptoms and insecure attachment predict disability and quality of life in psoriasis independently from disease severity 30
Effects of TNF-α inhibition on pre-clinical enthesitis: observational study on 49 psoriatic patients 29
Satisfaction and attitudes toward systemic treatments for psoriasis: A cross-sectional study 29
The role of insomnia in the vulnerability to depressive and anxiety symptoms in atopic dermatitis adult patients 28
Spotlight on ixekizumab for the treatment of moderate-to-severe plaque psoriasis: design, development, and use in therapy 28
Atopic dermatitis in adolescents: Effectiveness and safety of dupilumab in a 16-week real-life experience during the COVID-19 pandemic in Italy 28
Dupilumab in adolescents with moderate to severe atopic dermatitis: a 32-week real-world experience during the COVID-19 pandemic 28
Tildrakizumab for treatment of moderate to severe psoriasis: an expert opinion of efficacy, safety, and use in special populations 27
The therapeutic advantages on BMV plaster in chronic plaque psoriasis. Results from a new european multicentric study 26
Effect of anti-tumor necrosis factor-alpha therapies on body mass index in patients with psoriasis 26
Influence of body mass index and weight on etanercept efficacy in patients with psoriasis: A retrospective study 26
Increased frequency of Ig heavy-chain HS1,2-A enhancer *2 allele in dermatitis herpetiformis, plaque psoriasis, and psoriatic arthritis 26
Omalizumab for chronic spontaneous urticaria in “complex” patients: Data from real-life clinical practice 26
Apremilast efficacy and safety in a psoriatic arthritis patient affected by HIV and HBV virus infections 26
Nail and enthesis assessment in patients with psoriatic disease by high frequency ultrasonography: findings from a single-centre cross-sectional study 25
From patients' needs to treatment outcomes in psoriasis: Results from the 'pSORRIDI' experience 25
Long-term treatment with etanercept monotherapy in a hemodialyzed patient with moderate-to-severe plaque-type psoriasis and psoriatic arthritis 25
Long-term experience with etanercept in psoriatic arthritis patients: A 3-year observational study 24
Treatment of severe psoriasis during pregnancy and breastfeeding: A therapeutic challenging case 24
Etanercept at different dosages in the treatment of generalized pustular psoriasis: A case series 23
Dimethyl Fumarate's Effectiveness and Safety in Psoriasis: A Real-Life Experience During the COVID-19 Pandemic 22
Treatment adherence with diclofenac 3% gel among patients with multiple actinic keratoses: an integrated low-intensity intervention program versus standard-of-care 22
Totale 3.740
Salva come PNG Salva come JPEG
Categoria #
all - tutte 23.679
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 23.679
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020561 0 0 0 24 18 93 176 35 101 27 6 81
2020/2021569 6 77 3 80 80 6 104 5 95 6 94 13
2021/2022334 7 4 19 11 24 4 3 25 66 4 37 130
2022/20231.613 121 66 15 139 98 133 5 99 840 10 58 29
2023/2024324 59 25 35 27 25 88 4 7 0 22 7 25
2024/2025260 54 30 172 4 0 0 0 0 0 0 0 0
Totale 4.017